Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSCPA.L Regulatory News (SCPA)

  • There is currently no data for SCPA

AGM Statement

23 Jul 2019 07:00

RNS Number : 3337G
Scapa Group PLC
23 July 2019
 

 

 

 

 

23 July 2019

 

LEI No. 213800QIPVTK5ES5UU36

 

 

Scapa Group plc

AGM Statement

 

 

Scapa Group plc (AIM: SCPA) is holding its Annual General Meeting at 10:30am today. At the meeting, Larry Pentz, Chairman of Scapa Group, will provide the following update.

 

The Group's trading performance for the first quarter is in line with the Board's expectations.

 

Q1 Statutory Basis

Q1 Continuing Basis1

Organic (excl Syst2 & CVT3)

Growth (Reported)

Growth (constant FX)

Growth (Reported)

Growth (constant FX)

Growth (Reported)

Growth (constant FX)

Healthcare Revenues

47.8%

41.5%

40.6%

34.6%

7.9%

3.5%

Industrial Revenues

4.5%

2.8%

4.5%

2.8%

4.5%

2.8%

Scapa Group Revenues

21.6%

18.4%

18.7%

15.6%

5.6%

3.1%

 

The integration and consolidation projects are proceeding according to plan and the Company continues to seek additional opportunities to deliver long-term sustainable growth.

 

The Board considers Scapa to be well positioned to make further progress against its strategic objectives and remains confident in the Group's outlook.

 

1 Excluding IFRS 15 provision release. A contract liability provision was created as a result of the acquisition of Systagenix in line with the requirements of IFRS 15 and this is excluded on a 'continuing' basis as it represents a non-cash item. This provision will be released on a straight-line basis over a five-year period, in line with the exclusive supply contract

² Systagenix

³ ConvaTec

 

For further information:

 

Scapa Group plc

Heejae Chae - Group Chief Executive

Oskar Zahn - Chief Financial Officer

 

Tel: 0161 301 7430

Numis Securities Limited

(Nominated Adviser/Joint Broker)

 

Mark Lander, Richard Thomas

Tel: 020 7260 1000

Berenberg

(Joint Broker)

 

Chris Bowman, Toby Flaux

 

Tel: 020 3207 7800

FTI Consulting

(Media Relations)

 

Brett Pollard, Victoria Foster Mitchell

Tel: 020 3727 1000

 

 

About Scapa Group plc

Scapa Group plc is a diversified Healthcare and Industrial company focused on bringing best-in-class innovation, design and manufacturing solutions to its customers.

 

Healthcare

Scapa Healthcare is the trusted strategic partner of choice for the world's leading companies in Advanced Wound Care, Consumer Wellness and Medical Device Fixation. We partner with the top global MedTech companies to develop and manufacture innovative skin friendly medical device fixation and topical solutions, from inception through to market delivery, from our state-of-the-art facilities.

 

For further information, please visit www.scapahealthcare.com

 

Industrial

Scapa Industrial is a global supplier of bonding solutions and manufacturer of adhesive-based products which offer meaningful value in industrial applications due to their lightweight, easy-to-apply properties. We are recognised for our unparalleled range of products, including adhesive tapes, films and foams, and we can engineer custom designs for even the most unique applications.

 

For further information, please visit www.scapaindustrial.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGMPGUGGMUPBGQP
Date   Source Headline
1st Mar 201710:22 amRNSAdditional Listing
23rd Feb 201711:03 amRNSHolding(s) in Company
16th Feb 20179:21 amRNSHolding(s) in Company
7th Feb 20174:16 pmRNSBlock listing Interim Review
3rd Feb 20173:53 pmRNSHolding(s) in Company
26th Jan 201710:10 amRNSDirector/PDMR Shareholding
25th Jan 20174:33 pmRNSBlock listing Interim Review
25th Jan 201711:49 amRNSHolding(s) in Company
23rd Jan 20179:18 amRNSDirector/PDMR Shareholding
9th Jan 20179:41 amRNSAdditional Listing
22nd Dec 20162:15 pmRNSAdditional Listing
15th Dec 20167:00 amRNSDirectorate Change
13th Dec 20161:29 pmRNSAdditional Listing
24th Nov 20164:30 pmRNSDirector/PDMR Shareholding
24th Nov 20164:20 pmRNSDirector/PDMR Shareholding
22nd Nov 20164:20 pmRNSAdditional Listing
22nd Nov 20167:00 amRNSHalf-year Report
12th Oct 20167:00 amRNSTrading Statement
27th Sep 20162:53 pmRNSDirector/PDMR Shareholding
21st Sep 20161:51 pmRNSAdditional Listing
6th Sep 201610:24 amRNSAdditional Listing
2nd Sep 201611:20 amRNSBlock listing Interim Review
31st Aug 20169:14 amRNSTotal Voting Rights
26th Aug 20167:00 amRNSDirector/PDMR Shareholding
12th Aug 201611:24 amRNSBlock listing Interim Review
11th Aug 20161:30 pmRNSDirector/PDMR Shareholding
10th Aug 201610:08 amRNSDirector/PDMR Shareholding
19th Jul 20164:58 pmRNSAdditional Listing
19th Jul 20167:00 amRNSAGM Statement
11th Jul 20163:48 pmRNSDirector/PDMR Shareholding
5th Jul 20162:25 pmRNSHolding(s) in Company
1st Jul 20162:58 pmRNSDirector/PDMR Shareholding
1st Jun 20163:49 pmRNSAdditional Listing
1st Jun 20167:00 amRNSAppointment of Joint Broker
24th May 20167:00 amRNSAcquisition
24th May 20167:00 amRNSFinal Results
18th May 201610:01 amRNSAdditional Listing
11th May 201610:45 amRNSHolding(s) in Company
18th Apr 20167:00 amRNSDirectorate Change
14th Apr 20167:00 amRNSTrading Statement
2nd Mar 20169:06 amRNSBlocklisting Interim Review
8th Feb 20169:49 amRNSBlocklisting Interim Review
28th Jan 20167:00 amRNSDirectorate Change
31st Dec 20157:00 amRNSTotal Voting Rights
15th Dec 20159:57 amRNSHolding(s) in Company
14th Dec 20158:26 amRNSHolding(s) in Company
14th Dec 20158:21 amRNSDirector/PDMR Shareholding
8th Dec 201511:46 amRNSHolding(s) in Company
8th Dec 201511:42 amRNSHolding(s) in Company
1st Dec 201510:52 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.